How to buy Abeona Therapeutics stock | $0.891

Abeona Therapeutics Inc is a biotechnology business based in the US. Abeona Therapeutics shares (ABEO) are listed on the NASDAQ and all prices are listed in US Dollars. Abeona Therapeutics employs 76 staff and has a trailing 12-month revenue of around 0.00.

Abeona Therapeutics stock price (NASDAQ: ABEO)

Use our graph to track the performance of ABEO stocks over time.

Abeona Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$0.89
52-week range	$0.84 - $3.79
50-day moving average	$1.15
200-day moving average	$1.42
Wall St. target price	$5.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.58

Buy Abeona Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Abeona Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Abeona Therapeutics price performance over time

Historical closes compared with the close of $0.891 from 2021-10-18

1 week (2021-10-12)	-0.71%
1 month (2021-09-17)	-25.75%
3 months (2021-07-19)	-27.56%
6 months (2021-04-19)	-36.81%

1 year (2020-10-19)	-31.98%
2 years (2019-10-18)	-58.94%
3 years (2018-10-19)	9.34
5 years (2016-10-19)	7.76

Abeona Therapeutics financials

Revenue TTM	$10 million
Gross profit TTM	$-20,139,000
Return on assets TTM	-20.78%
Return on equity TTM	-52.91%
Profit margin	0%
Book value	$0.83
Market capitalisation	$92.1 million

TTM: trailing 12 months

Shorting Abeona Therapeutics shares

There are currently 2.8 million Abeona Therapeutics shares held short by investors – that's known as Abeona Therapeutics's "short interest". This figure is 12.4% down from 3.2 million last month.

There are a few different ways that this level of interest in shorting Abeona Therapeutics shares can be evaluated.

Abeona Therapeutics's "short interest ratio" (SIR)

Abeona Therapeutics's "short interest ratio" (SIR) is the quantity of Abeona Therapeutics shares currently shorted divided by the average quantity of Abeona Therapeutics shares traded daily (recently around 479960.47297297). Abeona Therapeutics's SIR currently stands at 5.92. In other words for every 100,000 Abeona Therapeutics shares traded daily on the market, roughly 5920 shares are currently held short.

However Abeona Therapeutics's short interest can also be evaluated against the total number of Abeona Therapeutics shares, or, against the total number of tradable Abeona Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abeona Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Abeona Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0313% of the tradable shares (for every 100,000 tradable Abeona Therapeutics shares, roughly 31 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Abeona Therapeutics.

Find out more about how you can short Abeona Therapeutics stock.

Abeona Therapeutics share dividends

We're not expecting Abeona Therapeutics to pay a dividend over the next 12 months.

Have Abeona Therapeutics's shares ever split?

Abeona Therapeutics's shares were split on a 1:50 basis on 23 October 2014. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Abeona Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Abeona Therapeutics shares which in turn could have impacted Abeona Therapeutics's share price.

Abeona Therapeutics share price volatility

Over the last 12 months, Abeona Therapeutics's shares have ranged in value from as little as $0.84 up to $3.79. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abeona Therapeutics's is 1.5169. This would suggest that Abeona Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Abeona Therapeutics overview

Abeona Therapeutics Inc. , a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc.

Frequently asked questions

What percentage of Abeona Therapeutics is owned by insiders or institutions?
Currently 15.731% of Abeona Therapeutics shares are held by insiders and 28.294% by institutions. How many people work for Abeona Therapeutics?
Latest data suggests 76 work at Abeona Therapeutics. When does the fiscal year end for Abeona Therapeutics?
Abeona Therapeutics's fiscal year ends in December. Where is Abeona Therapeutics based?
Abeona Therapeutics's address is: 1330 Avenue of the Americas, New York, NY, United States, 10019 What is Abeona Therapeutics's ISIN number?
Abeona Therapeutics's international securities identification number is: US00289Y1073 What is Abeona Therapeutics's CUSIP number?
Abeona Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00289Y107